SOX2 is often highly expressed in glioblastoma and its knockdown reduces proliferation and tumourigenicity in glioblastoma tumour-initiating cells (de la Rocha et al., 2014; Gangemi et al., 2009; Garros-Regulez et al., 2016). The gene discussed is SOX2; the disease is glioblastoma.